|
Giving medicines a new life: EU should foster patients’ access to Value Added Medicines |
Medicines for Europe |
Wed, 11/30/2022 |
Health & Consumers |
|
Pharmaceutical legislation reforms must support equitable access to medicine in Central and Eastern Europe and security of medicines supplies |
Medicines for Europe |
Thu, 11/17/2022 |
Health & Consumers |
|
Proposals on wastewater treatment will jeopardise patient access to medicines without helping green transition |
Medicines for Europe |
Thu, 10/27/2022 |
Health & Consumers |
|
Energy Council (TTE) – Medicines for Europe Open letter to European Energy Ministers and responsible European Commissioners on inflation and energy costs impacting the supply of essential generic medicines |
Medicines for Europe |
Wed, 09/28/2022 |
Health & Consumers |
|
EMA/HMA share definitive EU-wide position on biosimilar medicines interchangeability |
Medicines for Europe |
Tue, 09/20/2022 |
Health & Consumers |
|
Medicines for Europe warns strongly against energy rationing for medicines production |
Medicines for Europe |
Wed, 07/20/2022 |
Health & Consumers |
|
The off-patent medicines industry is a vital part of the solution for healthcare resilience |
Medicines for Europe |
Thu, 06/30/2022 |
Health & Consumers |
|
Smart reform of EU pharma and IP legislation key to boosting access to essential medicines |
Medicines for Europe |
Thu, 06/30/2022 |
Health & Consumers |
|
EU can do more for patients with smart use of biosimilar medicines |
Medicines for Europe |
Fri, 04/29/2022 |
Health & Consumers |
|
Central & Eastern European patients have inequitable access to medicines for life-threatening conditions |
Medicines for Europe |
Mon, 04/25/2022 |
Health & Consumers |
|
Repurposing: a golden opportunity for patient centric health investment in Europe |
Medicines for Europe |
Wed, 04/06/2022 |
Health & Consumers |
|
Electronic product information: new report shows it is time to move from principles to action |
Medicines for Europe |
Fri, 02/25/2022 |
Health & Consumers |
|
The European Commission needs to prioritise equitable access to biosimilar medicines in Europe |
Medicines for Europe |
Tue, 01/25/2022 |
Health & Consumers |
|
Regulatory reforms critical to improve patient access to medicines |
Medicines for Europe |
Mon, 01/24/2022 |
Health & Consumers |
|
Stronger mandate for European Medicines Agency should prioritise patient access to medicines |
Medicines for Europe |
Mon, 01/24/2022 |
Health & Consumers |
|
Biosimilar medicines have delivered 18BN€ total savings for Europe but more action needed to translate this potential into patient access and sustainable health systems |
Medicines for Europe |
Thu, 12/16/2021 |
Health & Consumers |
|
Commission study highlights market framework conditions are main driver for medicines shortages |
Medicines for Europe |
Fri, 12/10/2021 |
Health & Consumers |
|
Access to essential medicines threatened by combination of increasing inflation and potential further price cuts in EU countries |
Medicines for Europe |
Fri, 11/26/2021 |
Health & Consumers |
|
European Parliament report calls for increased use of off-patent medicines to improve patient access |
Medicines for Europe |
Thu, 11/25/2021 |
Health & Consumers |
|
The EU must stop the offshoring of essential medicines manufacturing investments: ambitious, open and coherent policies must support competitive, robust and sustainable production of APIs and medicines |
Medicines for Europe |
Tue, 11/23/2021 |
Global Europe |
|
Adjustments to IP framework needed to improve access to medicines in Europe |
Medicines for Europe |
Tue, 11/16/2021 |
Science & Policymaking |
|
Access to medicines critical in European Parliament vote on EU IP action plan |
Medicines for Europe |
Fri, 11/12/2021 |
Health & Consumers |
|
EU must learn from Covid-19 to improve crisis preparedness and response for the future |
Medicines for Europe |
Tue, 11/09/2021 |
Health & Consumers |
|
European Commission pilot project on repurposing brings value added innovation to life |
Medicines for Europe |
Thu, 10/28/2021 |
Health & Consumers |
|
Baton passes from Christoph Stoller to Rebecca Guntern as President of Medicines for Europe |
Medicines for Europe |
Fri, 10/01/2021 |
Health & Consumers |
|
HERA must address outstanding weaknesses in EU pharma framework to be successful |
Medicines for Europe |
Thu, 09/16/2021 |
Health & Consumers |
|
Orphan and paediatric reform should strive to improve access to medicine for rare disease patients and children |
Medicines for Europe |
Fri, 07/30/2021 |
Health & Consumers |
|
EU must take the lead to ensure security of supply for medicines |
Medicines for Europe |
Wed, 06/16/2021 |
Health & Consumers |
|
Open borders that prioritise essential goods key to medicines supply in Europe |
Medicines for Europe |
Wed, 06/02/2021 |
Health & Consumers |
|
EU Industrial strategy should be key to improving medicines supply chains |
Medicines for Europe |
Mon, 05/17/2021 |
Health & Consumers |
